Andrew White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrew White has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Sarah E. Church
NanoString Technologies, Inc., Seattle, USA
3 shared publications - Brent T. Harris
Georgetown University Medical Center 5 Department of Pathology Washington, District of Columbia
2 shared publications - Briana M. Hudson
NanoString Technologies Inc., Seattle, Washington, USA
2 shared publications - Emily Maisonet
Medstar Georgetown University Hospital, Washington, USA
2 shared publications - Krysta Chaldekas
Medstar Georgetown University Hospital, Washington, USA
2 shared publications - Sarah Warren
NanoString Technologies, Seattle, WA 98109, USA
2 shared publications
Latest Publications
- Open Access
- 8 September 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-13
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
Background: Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma. Methods: A retrospective study was carried out in patients with unresectable/metastatic melanoma (stage IIIb–IV), treated with anti-PD-1 in the first line setting, to better explore the role and the timing of neutrophil/lymphocyte ratio (NLR) as potential biomarker of response. The relationship of NLR with inflammation-immune mediators and the underlying negative effect of raising NLR during immunotherapy, have been investigated with transcriptomic gene analysis. Results: The results confirmed previous findings that a high baseline NLR is associated with a poorer prognosis and with higher serum level of lactate dehydrogenase (LDH), regardless of the presence of brain metastases. The transcriptomic analysis showed that high baseline NLR is associated with a characteristic gene signature CCNA1, LDHA and IL18R1, which correlates with inflammation and tumorigenesis. Conversely, low baseline NLR is associated with the signature CD3, SH2D1A, ZAP70 and CD45RA, linked to the immune-activation. The genes positively associated with NLR (CD39 (ENTPD1), PTEN, MYD88, MMP9 and LDH) are involved in processes of immunosuppression, inflammation and tumor-promoting activity. Increased expression of CD39 correlated with TGFβ2, a marker of the N2 neutrophils with immunosuppressive activity. Conclusions: These results suggest that increasing NLR is associated with an increased neutrophil population, with polarization to the N2 phenotype, and this process may be the basis for the negatively prognostic role of NLR.
- 8 September 2023
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 21 (1) , 1-13
Open AccessCD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
Background: Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma. Methods: A retrospective study was carried out in patients with unresectable/metastatic melanoma (stage IIIb–IV), treated with anti-PD-1 in the first line setting, to better explore the role and the timing of neutrophil/lymphocyte ratio (NLR) as potential biomarker of response. The relationship of NLR with inflammation-immune mediators and the underlying negative effect of raising NLR during immunotherapy, have been investigated with transcriptomic gene analysis. Results: The results confirmed previous findings that a high baseline NLR is associated with a poorer prognosis and with higher serum level of lactate dehydrogenase (LDH), regardless of the presence of brain metastases. The transcriptomic analysis showed that high baseline NLR is associated with a characteristic gene signature CCNA1, LDHA and IL18R1, which correlates with inflammation and tumorigenesis. Conversely, low baseline NLR is associated with the signature CD3, SH2D1A, ZAP70 and CD45RA, linked to the immune-activation. The genes positively associated with NLR (CD39 (ENTPD1), PTEN, MYD88, MMP9 and LDH) are involved in processes of immunosuppression, inflammation and tumor-promoting activity. Increased expression of CD39 correlated with TGFβ2, a marker of the N2 neutrophils with immunosuppressive activity. Conclusions: These results suggest that increasing NLR is associated with an increased neutrophil population, with polarization to the N2 phenotype, and this process may be the basis for the negatively prognostic role of NLR.
- Open Access
Use of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma
Although immune checkpoint inhibitors (ICIs) have significantly improved the oncological outcomes, about one-third of patients affected by clear cell renal cell carcinoma (ccRCC) still experience recurrence. Current prognostic algorithms, such as the Leibovich score (LS), rely on morphological features manually assessed by pathologists and are therefore subject to bias. Moreover, these tools do not consider the heterogeneous molecular milieu present in the Tumour Microenvironment (TME), which may have prognostic value. We systematically developed a semi-automated method to investigate 62 markers and their combinations in 150 primary ccRCCs using Multiplex Immunofluorescence (mIF), NanoString GeoMx® Digital Spatial Profiling (DSP) and Artificial Intelligence (AI)-assisted image analysis in order to find novel prognostic signatures and investigate their spatial relationship. We found that coexpression of cancer stem cell (CSC) and epithelial-to-mesenchymal transition (EMT) markers such as OCT4 and ZEB1 are indicative of poor outcome. OCT4 and the immune markers CD8, CD34, and CD163 significantly stratified patients at intermediate LS. Furthermore, augmenting the LS with OCT4 and CD34 improved patient stratification by outcome. Our results support the hypothesis that combining molecular markers has prognostic value and can be integrated with morphological features to improve risk stratification and personalised therapy. To conclude, GeoMx® DSP and AI image analysis are complementary tools providing high multiplexing capability required to investigate the TME of ccRCC, while reducing observer bias.
Open AccessUse of High-Plex Data Reveals Novel Insights into the Tumour Microenvironment of Clear Cell Renal Cell Carcinoma
Although immune checkpoint inhibitors (ICIs) have significantly improved the oncological outcomes, about one-third of patients affected by clear cell renal cell carcinoma (ccRCC) still experience recurrence. Current prognostic algorithms, such as the Leibovich score (LS), rely on morphological features manually assessed by pathologists and are therefore subject to bias. Moreover, these tools do not consider the heterogeneous molecular milieu present in the Tumour Microenvironment (TME), which may have prognostic value. We systematically developed a semi-automated method to investigate 62 markers and their combinations in 150 primary ccRCCs using Multiplex Immunofluorescence (mIF), NanoString GeoMx® Digital Spatial Profiling (DSP) and Artificial Intelligence (AI)-assisted image analysis in order to find novel prognostic signatures and investigate their spatial relationship. We found that coexpression of cancer stem cell (CSC) and epithelial-to-mesenchymal transition (EMT) markers such as OCT4 and ZEB1 are indicative of poor outcome. OCT4 and the immune markers CD8, CD34, and CD163 significantly stratified patients at intermediate LS. Furthermore, augmenting the LS with OCT4 and CD34 improved patient stratification by outcome. Our results support the hypothesis that combining molecular markers has prognostic value and can be integrated with morphological features to improve risk stratification and personalised therapy. To conclude, GeoMx® DSP and AI image analysis are complementary tools providing high multiplexing capability required to investigate the TME of ccRCC, while reducing observer bias.
- Open Access
- 27 November 2021
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 19 (1) , 1-14
The tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
Background: The characterization of the immune component of the tumor microenvironment (TME) of human epidermal growth factor receptor 2 positive (HER2+) breast cancer has been limited. Molecular and spatial characterization of HER2+ TME of primary, recurrent, and metastatic breast tumors has the potential to identify immune mediated mechanisms and biomarker targets that could be used to guide selection of therapies.Methods: We examined 15 specimens from eight patients with HER2+ breast cancer: 10 primary breast tumors (PBT), two soft tissue, one lung, and two brain metastases (BM). Using molecular profiling by bulk gene expression TME signatures, including the Tumor Inflammation Signature (TIS) and PAM50 subtyping, as well as spatial characterization of immune hot, warm, and cold regions in the stroma and tumor epithelium using 64 protein targets on the GeoMx Digital Spatial Profiler.Results: PBT had higher infiltration of immune cells relative to metastatic sites and higher protein and gene expression of immune activation markers when compared to metastatic sites. TIS scores were lower in metastases, particularly in BM. BM also had less immune infiltration overall, but in the stromal compartment with the highest density of immune infiltration had similar levels of T cells that were less activated than PBT stromal regions suggesting immune exclusion in the tumor epithelium.Conclusions: Our findings show stromal and tumor localized immune cells in the TME are more active in primary versus metastatic disease. This suggests patients with early HER2+ breast cancer could have more benefit from immune-targeting therapies than patients with advanced disease.
- 27 November 2021
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 19 (1) , 1-14
Open AccessThe tumor immune microenvironment of primary and metastatic HER2− positive breast cancers utilizing gene expression and spatial proteomic profiling
Background: The characterization of the immune component of the tumor microenvironment (TME) of human epidermal growth factor receptor 2 positive (HER2+) breast cancer has been limited. Molecular and spatial characterization of HER2+ TME of primary, recurrent, and metastatic breast tumors has the potential to identify immune mediated mechanisms and biomarker targets that could be used to guide selection of therapies.Methods: We examined 15 specimens from eight patients with HER2+ breast cancer: 10 primary breast tumors (PBT), two soft tissue, one lung, and two brain metastases (BM). Using molecular profiling by bulk gene expression TME signatures, including the Tumor Inflammation Signature (TIS) and PAM50 subtyping, as well as spatial characterization of immune hot, warm, and cold regions in the stroma and tumor epithelium using 64 protein targets on the GeoMx Digital Spatial Profiler.Results: PBT had higher infiltration of immune cells relative to metastatic sites and higher protein and gene expression of immune activation markers when compared to metastatic sites. TIS scores were lower in metastases, particularly in BM. BM also had less immune infiltration overall, but in the stromal compartment with the highest density of immune infiltration had similar levels of T cells that were less activated than PBT stromal regions suggesting immune exclusion in the tumor epithelium.Conclusions: Our findings show stromal and tumor localized immune cells in the TME are more active in primary versus metastatic disease. This suggests patients with early HER2+ breast cancer could have more benefit from immune-targeting therapies than patients with advanced disease.
- Open Access
- 29 June 2021
- Published by Springer Nature in Research Square
The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling
Background The characterization of the immune component of the tumor microenvironment (TME) of human epidermal growth factor receptor 2 positive (HER2+) breast cancer has been limited. Molecular and spatial characterization of HER2 + TME of primary, recurrent, and metastatic breast tumors has the potential to identify immune mediated mechanisms and biomarker targets that could be used to guide selection of therapies. Methods We examined 15 specimens from eight patients with HER2 + breast cancer: 10 primary breast tumors (PBT), two soft tissue, one lung, and two brain metastases (BM). Using molecular profiling by bulk gene expression TME signatures, including the Tumor Inflammation Signature (TIS) and PAM50 subtyping, as well as spatial characterization of immune hot, warm, and cold regions in the stroma and tumor epithelium using 64 protein targets on the GeoMx Digital Spatial Profiler. Results PBT had higher infiltration of immune cells relative to metastatic sites and higher protein and gene expression of immune activation markers when compared to metastatic sites. TIS scores were lower in metastases, particularly in BM. BM also had less immune infiltration overall, but in the stromal compartment with the highest density of immune infiltration had similar levels of T cells that were less activated than PBT stromal regions suggesting immune exclusion in the tumor epithelium. Conclusions Our findings show stromal and tumor localized immune cells in the TME are more active in primary versus metastatic disease. This suggests patients with early HER2 + breast cancer could have more benefit from immune-targeting therapies than patients with advanced disease.
- 29 June 2021
- Published by Springer Nature in Research Square
Open AccessThe tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling
Background The characterization of the immune component of the tumor microenvironment (TME) of human epidermal growth factor receptor 2 positive (HER2+) breast cancer has been limited. Molecular and spatial characterization of HER2 + TME of primary, recurrent, and metastatic breast tumors has the potential to identify immune mediated mechanisms and biomarker targets that could be used to guide selection of therapies. Methods We examined 15 specimens from eight patients with HER2 + breast cancer: 10 primary breast tumors (PBT), two soft tissue, one lung, and two brain metastases (BM). Using molecular profiling by bulk gene expression TME signatures, including the Tumor Inflammation Signature (TIS) and PAM50 subtyping, as well as spatial characterization of immune hot, warm, and cold regions in the stroma and tumor epithelium using 64 protein targets on the GeoMx Digital Spatial Profiler. Results PBT had higher infiltration of immune cells relative to metastatic sites and higher protein and gene expression of immune activation markers when compared to metastatic sites. TIS scores were lower in metastases, particularly in BM. BM also had less immune infiltration overall, but in the stromal compartment with the highest density of immune infiltration had similar levels of T cells that were less activated than PBT stromal regions suggesting immune exclusion in the tumor epithelium. Conclusions Our findings show stromal and tumor localized immune cells in the TME are more active in primary versus metastatic disease. This suggests patients with early HER2 + breast cancer could have more benefit from immune-targeting therapies than patients with advanced disease.
- Top Cited PapersOpen Access
- 21 February 2017
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1) , 18
Gene expression markers of Tumor Infiltrating Leukocytes
Background For many years the standard approach to staging of the mediastinum in non-small cell lung cancer (NSCLC) has been surgical using cervical mediastinoscopy, left anterior mediastinotomy or video assisted thoracoscopic surgery (VATS). More recently endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) have been reported. We conducted a randomised phase III trial to compare surgical staging versus endoscopic staging. The primary endpoint was detection of mediastinal nodal metastasis (N2/3); secondary endpoints were complication and futile thoracotomy rates. Methods Consecutive patients with potentially resectable (suspected) NSCLC in whom invasive mediastinal staging was indicated based on CT or PET-CT findings were randomly assigned to either Arm A, surgical staging or Arm B, combined EBUS/EUS (followed by surgical staging if endoscopic findings were negative for malignancy). Surgical staging involved mediastinoscopy and/or mediastinotomy and/or VATS. Subsequently, in the absence of mediastinal disease, thoracotomy with systematic lymph node sampling was performed. 240 pts were required to show a 20% increase in sensitivity (power 80% and α=0.05) to detect mediastinal nodal disease with a prevalence of 50%. Results 118 patients were randomised to Arm A and 123 to Arm B. The sensitivity for detection of mediastinal metastases by surgical staging in Arm A was 80% (95% CI, 68 to 89) vs 94% (95% CI, 85 to 98) for endoscopic (± surgical) staging in Arm B (p=0.04). Nodal metastases were found in 41 (35%) of surgically staged patients in Arm A and 62 patients (50%) (56 by EBUS/EUS + 6 by subsequent surgical staging) in Arm B (p=0.019). Overall, the prevalence of mediastinal disease in each arm was similar (p=0.24). Thoracotomy was considered futile in 21 (18%) in those staged in Arm A vs 8 patients (7%) in Arm B (p=0.009). Complication rate was similar in both arms (6 vs 7 patients, p=0.8); however, 12 of 13 complications were due to surgical staging procedures. Conclusions Mediastinal staging for NSCLC should commence with combined EBUS/EUS (followed by surgical staging if endoscopic findings are negative for malignancy) as this improves the detection of nodal metastases and reduces futile thoracotomies compared to surgical staging alone.
- 21 February 2017
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 5 (1) , 18
Top Cited PapersOpen AccessGene expression markers of Tumor Infiltrating Leukocytes
Background For many years the standard approach to staging of the mediastinum in non-small cell lung cancer (NSCLC) has been surgical using cervical mediastinoscopy, left anterior mediastinotomy or video assisted thoracoscopic surgery (VATS). More recently endobronchial ultrasound (EBUS) and endoscopic ultrasound (EUS) have been reported. We conducted a randomised phase III trial to compare surgical staging versus endoscopic staging. The primary endpoint was detection of mediastinal nodal metastasis (N2/3); secondary endpoints were complication and futile thoracotomy rates. Methods Consecutive patients with potentially resectable (suspected) NSCLC in whom invasive mediastinal staging was indicated based on CT or PET-CT findings were randomly assigned to either Arm A, surgical staging or Arm B, combined EBUS/EUS (followed by surgical staging if endoscopic findings were negative for malignancy). Surgical staging involved mediastinoscopy and/or mediastinotomy and/or VATS. Subsequently, in the absence of mediastinal disease, thoracotomy with systematic lymph node sampling was performed. 240 pts were required to show a 20% increase in sensitivity (power 80% and α=0.05) to detect mediastinal nodal disease with a prevalence of 50%. Results 118 patients were randomised to Arm A and 123 to Arm B. The sensitivity for detection of mediastinal metastases by surgical staging in Arm A was 80% (95% CI, 68 to 89) vs 94% (95% CI, 85 to 98) for endoscopic (± surgical) staging in Arm B (p=0.04). Nodal metastases were found in 41 (35%) of surgically staged patients in Arm A and 62 patients (50%) (56 by EBUS/EUS + 6 by subsequent surgical staging) in Arm B (p=0.019). Overall, the prevalence of mediastinal disease in each arm was similar (p=0.24). Thoracotomy was considered futile in 21 (18%) in those staged in Arm A vs 8 patients (7%) in Arm B (p=0.009). Complication rate was similar in both arms (6 vs 7 patients, p=0.8); however, 12 of 13 complications were due to surgical staging procedures. Conclusions Mediastinal staging for NSCLC should commence with combined EBUS/EUS (followed by surgical staging if endoscopic findings are negative for malignancy) as this improves the detection of nodal metastases and reduces futile thoracotomies compared to surgical staging alone.